E4NA Stock Overview
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arovella Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.13 |
| 52 Week Low | AU$0.044 |
| Beta | -0.023 |
| 11 Month Change | -6.36% |
| 3 Month Change | 22.62% |
| 1 Year Change | 131.46% |
| 33 Year Change | 478.65% |
| 5 Year Change | 128.89% |
| Change since IPO | -94.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| E4NA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -8.8% | -7.0% | -0.4% |
| 1Y | 131.5% | -21.6% | 7.1% |
Return vs Industry: E4NA exceeded the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: E4NA exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| E4NA volatility | |
|---|---|
| E4NA Average Weekly Movement | 10.2% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E4NA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: E4NA's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michael Baker | www.arovella.com |
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally. The company product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021.
Arovella Therapeutics Limited Fundamentals Summary
| E4NA fundamental statistics | |
|---|---|
| Market cap | €117.86m |
| Earnings (TTM) | -€5.43m |
| Revenue (TTM) | €1.21m |
97.2x
P/S Ratio-21.7x
P/E RatioIs E4NA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E4NA income statement (TTM) | |
|---|---|
| Revenue | AU$1.95m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.95m |
| Other Expenses | AU$10.70m |
| Earnings | -AU$8.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0083 |
| Gross Margin | 100.00% |
| Net Profit Margin | -448.03% |
| Debt/Equity Ratio | 0% |
How did E4NA perform over the long term?
See historical performance and comparison